IMR Press / RCM / Volume 24 / Issue 3 / DOI: 10.31083/j.rcm2403072
Open Access Original Research
Development and Validation of a Nomogram for Balloon Pulmonary Angioplasty-Related Complications in Patients with Chronic Thromboembolic Pulmonary Hypertension
Show Less
1 Center for Respiratory and Pulmonary Vascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, National Clinical Research Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, 100037 Beijing, China
2 Department of Cardiology, Zhongshan Hospital, Shanghai Institute of Cardiovascular Diseases, Fudan University, 200032 Shanghai, China
*Correspondence: zhaozhihui2008@126.com (Zhihui Zhao); zhihongliufuwai@163.com (Zhihong Liu)
These authors contributed equally.
Rev. Cardiovasc. Med. 2023, 24(3), 72; https://doi.org/10.31083/j.rcm2403072
Submitted: 15 September 2022 | Revised: 14 November 2022 | Accepted: 22 November 2022 | Published: 28 February 2023
(This article belongs to the Special Issue Intravascular imaging and Cardiovascular intervention)
Copyright: © 2023 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.
Abstract

Background: Balloon pulmonary angioplasty (BPA)-related complications are not uncommon and could contribute to perioperative mortality. However, there is a lack of a prediction model for BPA-related complications. Methods: Data from consecutive patients diagnosed with chronic thromboembolic pulmonary hypertension (CTEPH) who underwent BPA were retrospectively analyzed. The primary outcome was BPA-related complications. The secondary outcomes were mortality and hemodynamics after BPA. Results: A total of 207 patients with 614 BPA sessions were included. Complications occurred during 63 sessions (10.26%) in 49 patients. Hemoptysis or hemosputum (6.51%) was the most common complication, whereas pulmonary reperfusion edema was rare (0.49%). Multivariable logistic regression identified that disease duration, mean pulmonary arterial pressure (mPAP) and the proportion of occlusion lesions were correlated with BPA complications. A nomogram was constructed accordingly, which had the highest area under curve (0.703) and was superior to previously reported predictors [nomogram vs. mPAP, net reclassification index (95% confidence interval (CI)), 0.215 (0.002, 0.427), p = 0.047; integrated discrimination index (95% CI), 0.059 (0.010, 0.109), p = 0.018]. The nomogram was found to be accurate based on validation and calibration (slope 0.978, Bier score 0.163). After adjusting for the number of BPA sessions in multivariable linear regression, the occurrence of complications was not associated with hemodynamic improvement after BPA. The 3-year survival was also comparable between patients with and without complications (98.0% vs. 94.8%, log-rank p = 0.503). Conclusions: The nomogram, comprising mPAP, the proportion of occlusion lesions and disease duration, could better predict BPA-related complications than previously reported single parameters. Distinctively, the occurrence of complications did not impair the beneficial impact of BPA on hemodynamics and survival. The occurrence of complications should not discourage patients from continuing BPA sessions.

Keywords
chronic thromboembolic pulmonary hypertension
balloon pulmonary angioplasty
right heart catheterization
complications
Funding
Z181100001718200/Beijing Municipal Science and Technology Project
7202168/Beijing Municipal Natural Science Foundation
2020-I2MC&T-B-055/Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences
2021-I2M-C&T-B-032/Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences
2019E-XK0402/“Double First-Class” Discipline Construction Fund of Peking Union Medical College and Chinese Academy of Medical Sciences
2020-2-4033/Capital’s Funds for Health Improvement and Research
2020-4-4035/Capital’s Funds for Health Improvement and Research
2021-016/Youth Fund of Zhongshan Hospital, Fudan University
22YF1439500/Yangfan Project of Science and Technology Commission of Shanghai Municipality
2022-GSP-GG-35/National High Level Hospital Clinical Research Funding
Figures
Fig. 1.
Share
Back to top